About EyeGate
EyeGate is a company based in Waltham (United States) founded in 1998.. EyeGate has raised $44.47 million across 13 funding rounds from investors including Armistice Capital, Emerge Capital Partners and NiXEN. The company has 12 employees as of December 31, 2022. EyeGate has completed 2 acquisitions, including Jade Therapeutics and Panoptes Pharma. EyeGate offers products and services including Drug Catalog, Special Offers, and Loyalty Programs. EyeGate operates in a competitive market with competitors including CorneaGen, Cellusion, Avedro, CorNeat Vision and Nu Eyne, among others.
- Headquarter Waltham, United States
- Employees 12 as on 31 Dec, 2022
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Kiora Pharmaceuticals, Inc.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$44.47 M (USD)
in 13 rounds
-
Latest Funding Round
$10.75 M (USD), Post-IPO
Aug 09, 2021
-
Investors
Armistice Capital
& 8 more
-
Employee Count
12
as on Dec 31, 2022
-
Investments & Acquisitions
Jade Therapeutics
& 1 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of EyeGate
EyeGate offers a comprehensive portfolio of products and services, including Drug Catalog, Special Offers, and Loyalty Programs. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Platform for purchasing various affordable medications online
Discounted products including bestsellers and weekly deals
Rewards system for repeat purchases and bonuses
Unlock access to complete
Unlock access to complete
Funding Insights of EyeGate
EyeGate has successfully raised a total of $44.47M across 13 strategic funding rounds. The most recent funding activity was a Post-IPO round of $10.75 million completed in August 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 13
- Last Round Post-IPO — $10.8M
-
First Round
First Round
(02 Nov 2006)
- Investors Count 9
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug, 2021 | Amount | Post-IPO - EyeGate | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - EyeGate | Valuation |
investors |
|
| Oct, 2019 | Amount | Post-IPO - EyeGate | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in EyeGate
EyeGate has secured backing from 9 investors, including institutional and venture fund investors. Prominent investors backing the company include Armistice Capital, Emerge Capital Partners and NiXEN. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity investments are directed toward France by NiXEN.
|
Founded Year | Domain | Location | |
|
Comprehensive strategic expertise in healthcare is provided by MEDICIS.
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by EyeGate
EyeGate has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Jade Therapeutics and Panoptes Pharma. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Small molecule therapies are developed for severe eye diseases.
|
2013 | ||||
|
Polymer-based products for ophthalmic drug delivery are developed using iontophoresis.
|
2012 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - EyeGate
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Eyegate Comparisons
Competitors of EyeGate
EyeGate operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as CorneaGen, Cellusion, Avedro, CorNeat Vision and Nu Eyne, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Therapeutic devices for corneal transplants are developed by CorneaGen.
|
|
| domain | founded_year | HQ Location |
iPS cell-based technology for corneal endothelium regeneration is developed.
|
|
| domain | founded_year | HQ Location |
Corneal collagen cross-linking technology is developed for ophthalmic applications.
|
|
| domain | founded_year | HQ Location |
Nanotechnology-based artificial corneal implants are developed for ophthalmic use.
|
|
| domain | founded_year | HQ Location |
Medical devices using electrical stimulation for health conditions are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Eyegate
Frequently Asked Questions about EyeGate
When was EyeGate founded?
EyeGate was founded in 1998 and raised its 1st funding round 8 years after it was founded.
Where is EyeGate located?
EyeGate is headquartered in Waltham, United States. It is registered at Waltham, Massachusetts, United States.
Is EyeGate a funded company?
EyeGate is a funded company, having raised a total of $44.47M across 13 funding rounds to date. The company's 1st funding round was a Post-IPO of $1.88M, raised on Nov 02, 2006.
How many employees does EyeGate have?
As of Dec 31, 2022, the latest employee count at EyeGate is 12.
What does EyeGate do?
EyeGate was founded in 1998 as a specialty pharmaceutical company based in Waltham, United States. Operations center on the development and commercialization of therapeutics and drug delivery systems for ocular disorders. The lead candidate, EGP-437, employs a reformulated dexamethasone phosphate delivered via the EyeGate II system. Phase 3 trials are underway for non-infectious anterior uveitis, while proof-of-concept studies address macular edema variants.
Who are the top competitors of EyeGate?
What products or services does EyeGate offer?
EyeGate offers Drug Catalog, Special Offers, and Loyalty Programs.
How many acquisitions has EyeGate made?
EyeGate has made 2 acquisitions, including Jade Therapeutics, and Panoptes Pharma.
Who are EyeGate's investors?
EyeGate has 9 investors. Key investors include Armistice Capital, Emerge Capital Partners, NiXEN, MEDICIS, and Ventech Solutions.